骶神经调控与A型肉毒毒素治疗难治性急迫性尿失禁的两年随机试验结果
这项多中心、开放标签、随机扩展试验纳入386例药物控制不佳的急迫性尿失禁女性,比较骶神经调控(SNM)与200U onabotulinumtoxinA(BTX)治疗24个月的效果。结果显示两组每日UUIE下降无显著差异(-3.88 vs -3.50,95%CI -0.14~0.89,p=0.15),但BTX组满意度和治疗认可度更高,而复发性尿路感染率更高(24% vs 10%,p<0.01)。
要点
- SNM与BTX在24个月内减少每日UUIE方面无显著差异。
- BTX组满意度和治疗认可度持续高于SNM组。
- BTX组复发性尿路感染率更高,SNM组修订/移除率低。
核心结论
- SNM和BTX均能持续改善难治性UUI,但BTX组满意度和治疗认可度更高,尿路感染风险也更高。
研究设计与样本
- 多中心、开放标签、随机扩展试验,2012年2月至2016年7月在美国9个医学中心进行,纳入386例药物控制不佳且每日3天内≥6次UUIE的女性。
- 参与者为治疗临床应答者:SNM置入后或BTX注射1个月后UUIE减少≥50%。
- SNM组194例,BTX组192例(200U onabotulinumtoxinA);SNM组全程可程控,BTX组6个月后允许追加两次注射。
主要发现
- 24个月内每日UUIE平均下降值SNM组-3.88 vs BTX组-3.50,95%CI -0.14~0.89,p=0.15,无显著差异。
- UUI完全缓解率、≥75%和≥50% UUIE减少率两组均无差异。
- BTX组满意度平均差异-9.14(95%CI -14.38~-3.90,p<0.001),治疗认可度平均差异-12.16(95%CI -17.7~-6.63,p<0.001),均持续至24个月。
- 复发性尿路感染BTX组24% vs SNM组10%(p<0.01);第二次注射后6%需间歇导尿。
- SNM组修订率3%,移除率9%。
关键数值与推荐
- 主要结局:24个月内每日UUIE平均变化,采用线性混合模型分析。
- 临床应答定义:SNM置入后或BTX注射1个月后UUIE减少≥50%。
- BTX剂量为200U onabotulinumtoxinA。
临床怎么用
- 对于药物难治性UUI女性,SNM和BTX均可作为持续有效的选择。
- 选择BTX时应告知复发性尿路感染风险及可能的间歇导尿需求。
- SNM修订和移除率较低,可依据患者偏好和风险耐受性个体化选择。
局限性
- 开放标签设计可能影响患者报告结局。
- 仅纳入临床应答者,结果可能不适用于无应答人群。
- 随访24个月,缺乏更长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urgency urinary incontinence (UUI) is a chronic condition for which sacral neuromodulation (SNM) (InterStim/Medtronic) and onabotulinumtoxinA (BTX) (BotoxA/Allergan) are utilized. These therapies have not been compared over extended time. OBJECTIVE: To compare UUI episodes (UUIE) over 24 mo following SNM or BTX. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized, extension trial (February 2012-July 2016) at nine US medical centers involving 386 women with ≥6 UUIE over 3 d inadequately managed by medications. Participants were clinical responders to treatment: ≥50% reduction in UUIEs after SNM placement or 1 mo post BTX. INTERVENTION: SNM (n=194) versus 200 U BTX (n=192). SNM reprogrammings occurred throughout the 24 mo. After 6 mo, two additional BTX injections were allowed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome: change in mean daily UUIE over 24 mo. SECONDARY OUTCOMES: no UUIE, ≥75% and ≥50% UUIE reduction; Overactive Bladder Questionnaire Short Form; Urinary Distress Inventory short form; Incontinence Impact Questionnaire; Patient Global Impression of Improvement; Overactive Bladder Satisfaction of Treatment Questionnaire; and adverse events (AEs). Primary analysis used a linear mixed model. RESULTS AND LIMITATIONS: Outcome data were available for 260/298 (87%) clinical responders. No difference in decreased mean UUIE was found over 24 mo (-3.88 vs -3.50 episodes/d,95% confidence interval [CI]=-0.14-0.89; p=0.15), with no differences in UUI resolution, ≥75% or ≥50% UUIE reduction. BTX group maintained higher satisfaction (mean difference=-9.14, 95% CI=-14.38--3.90; p<0.001), treatment endorsement (mean difference=-12.16, 95% CI=-17.7--6.63; p<0.001) through 24 mo. Other secondary measures did not differ. Recurrent urinary tract infections (UTIs) were higher after BTX (24% vs 10%; p<0.01), 6% required intermittent catheterization post second injection. SNM revision and removals occurred in 3% and 9% patients, respectively. CONCLUSIONS: Both treatments offered sustainable UUI improvement, and higher BTX dosing had low clean intermittent catheterization rates, but with UTI risk. SNM revision/removal rates were low due to standardized lead placement with strict treatment response definitions. PATIENT SUMMARY: We compared a large group of US women with severe urgency urinary incontinence (UUI) who received sacral neuromodulation (InterStim) or onabotulinumtoxinA (Botox A) therapy during a 2-yr period. We found that both therapies had similar success in reducing UUI symptoms, and adverse events were low. However, women in the BotoxA group had higher satisfaction and endorsement with their treatment, but with a higher chance of a urinary tract infection. We conclude that both therapies offer sustained reduction in daily incontinence over 2 yr.
引用
- Amundsen CL, Komesu YM, Chermansky C, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. 2018. PMID: 29482936. doi:10.1016/j.eururo.2018.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。